# Maternal Serum Alpha-fetoprotein Level May Predict the Presence of Morbid Adherent Placenta

> **NCT04082507** · — · UNKNOWN · sponsor: **rasha medhat abdul-hady** · enrollment: 150 (estimated)

## Conditions studied

- Placenta Accreta

## Interventions

- **DIAGNOSTIC_TEST:** Serum alpha-fetoproteine

## Key facts

- **NCT ID:** NCT04082507
- **Lead sponsor:** rasha medhat abdul-hady
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** UNKNOWN
- **Start date:** 2017-01-01
- **Primary completion:** 2019-08-30
- **Final completion:** 2019-08-30
- **Target enrollment:** 150 (ESTIMATED)
- **Last updated:** 2019-09-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04082507

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04082507, "Maternal Serum Alpha-fetoprotein Level May Predict the Presence of Morbid Adherent Placenta". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT04082507. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*